Published in J Thromb Haemost on June 01, 2007
Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell (2009) 4.50
A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood (2010) 1.83
Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood (2014) 1.81
Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest (2008) 1.59
In vivo roles of factor XII. Blood (2012) 1.37
Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood (2011) 1.22
The procoagulant and proinflammatory plasma contact system. Semin Immunopathol (2011) 1.06
Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates. J Thromb Haemost (2013) 0.99
Factor XI and contact activation as targets for antithrombotic therapy. J Thromb Haemost (2015) 0.94
Future prospects for contact factors as therapeutic targets. Hematology Am Soc Hematol Educ Program (2014) 0.85
The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy. Hematol Oncol Clin North Am (2016) 0.79
Combined cis-regulator elements as important mechanism affecting FXII plasma levels. Thromb Res (2009) 0.79
Coagulation and the vessel wall in pulmonary embolism. Pulm Circ (2013) 0.79
Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). Thromb Res (2015) 0.75
A history of late and very late stent thrombosis is not associated with increased activation of the contact system, a case control study. Thromb J (2010) 0.75
Introduction to haemostasis from a pharmacodynamic perspective. Br J Clin Pharmacol (2011) 0.75
Genetic fingerprinting in mouthwashes of patients after allogeneic bone marrow transplantation. Bone Marrow Transplant (1999) 2.53
Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther (2001) 2.51
Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet (2007) 2.50
Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost (2006) 2.22
Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Gut (2000) 2.08
Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost (1996) 2.07
Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res (2001) 1.98
Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology (2004) 1.87
Alternative end-joining in follicular lymphomas' t(14;18) translocation. Leukemia (2002) 1.71
Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions: novel insights into the mechanism of t(14;18) translocation. Blood (2000) 1.70
Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. J Thromb Haemost (2007) 1.68
Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol (2001) 1.68
Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke (2004) 1.66
Massive pulmonary embolism leading to cardiac arrest is associated with consumptive coagulopathy presenting as disseminated intravascular coagulation. J Thromb Haemost (2010) 1.60
Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost (2006) 1.58
Requirement of residual thymus to restore normal T-cell subsets after human allogeneic bone marrow transplantation. Transplantation (2000) 1.55
Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial. Clin Pharmacol Ther (1999) 1.50
Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost (2012) 1.48
Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther (2000) 1.46
Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood (2000) 1.45
Polymorphism in the tissue factor region is associated with basal but not endotoxin-induced tissue factor-mRNA levels in leukocytes. J Thromb Haemost (2006) 1.43
The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost (2005) 1.43
Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes (1997) 1.42
The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost (2003) 1.42
Studies on the effect of short-term oral dihydroergotamine and troxerutin in patients with varicose veins. Clin Pharmacol Ther (1994) 1.40
Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation (1997) 1.38
Evidence for a bicarbonate leak in the proximal tubule of the rat kidney. Pflugers Arch (1980) 1.36
Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. Neurology (2005) 1.28
High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia (2005) 1.24
Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. J Biol Chem (1995) 1.18
Evaluation of the new method Coaguchek for the determination of prothrombin time from capillary blood: comparison with Thrombotest on KC-1. Thromb Res (1995) 1.16
Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol (1998) 1.16
Multiplex PCR for rapid detection of T-cell receptor-gamma chain gene rearrangements in patients with lymphoproliferative diseases. Br J Haematol (1996) 1.15
High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol (2009) 1.13
Heparin blunts endotoxin-induced coagulation activation. Circulation (2000) 1.09
Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans. J Thromb Haemost (2006) 1.09
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood (1995) 1.07
The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost (1992) 1.06
Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas. Mod Pathol (2000) 1.06
CD5 expression in a lymphoma of the mucosa-associated lymphoid tissue (MALT)-type as a marker for early dissemination and aggressive clinical behaviour. Leuk Lymphoma (2001) 1.05
The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thromb Haemost (1997) 1.05
Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost (1999) 1.05
Fy phenotype and gender determine plasma levels of monocyte chemotactic protein. Transfusion (2001) 1.05
Thrombin generation in morbid obesity: significant reduction after weight loss. J Thromb Haemost (2010) 1.02
Effects of low dose endotoxemia on endothelial progenitor cells in humans. Atherosclerosis (2007) 1.02
Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia (2002) 1.01
Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost (2010) 1.01
A common C-->T polymorphism at nt 46 in the promoter region of coagulation factor XII is associated with decreased factor XII activity. Thromb Res (2001) 1.00
Sex differences in HAART-associated dyslipidaemia. AIDS (2001) 1.00
Improved characteristics of aPC-resistance assay: Coatest aPC resistance by predilution of samples with factor V deficient plasma. Am J Clin Pathol (1996) 1.00
Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia. Eur J Cancer (2011) 1.00
Haem oxygenase-1 genotype and cardiovascular adverse events in patients with peripheral artery disease. Eur J Clin Invest (2005) 0.99
Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost (2009) 0.97
Leukemia-free survival and mortality in patients with refractory or relapsed acute leukemia given marrow transplants from sibling and unrelated donors. Bone Marrow Transplant (1998) 0.97
Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL). Leukemia (2004) 0.96
Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int (1997) 0.96
Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol (2008) 0.96
The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost (1997) 0.95
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia (2004) 0.95
Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine (2008) 0.95
Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis (2008) 0.94
The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: evaluation of the incidence of FXII deficiency among 300 healthy blood donors. Thromb Haemost (1994) 0.94
Stability of coagulation factors in thawed, solvent/detergent-treated plasma during storage at 4 degrees C for 6 days. Vox Sang (2004) 0.94
Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood (1994) 0.93
Racial differences in endotoxin-induced tissue factor-triggered coagulation. J Thromb Haemost (2009) 0.93
Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis. Am J Clin Pathol (1999) 0.93
Sex differences in the association between albumin and all-cause and vascular mortality. Eur J Clin Invest (2009) 0.93
Persistent elevation and metabolic dependence of circulating E-selectin after delivery in women with gestational diabetes mellitus. J Clin Endocrinol Metab (1997) 0.92
Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med (1999) 0.92
Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes. Eur J Clin Invest (2006) 0.92
Protein S deficiency: a database of mutations--summary of the first update. Thromb Haemost (2000) 0.92
No impact of endogenous prothrombotic conditions on the risk of central venous line-related thrombotic events in children: results of the KIDCAT study (KIDs with Catheter Associated Thrombosis). J Thromb Haemost (2014) 0.92
Effects of endotoxemia on thrombopoiesis in men. Thromb Haemost (1999) 0.91
A rapid method for the isolation of genomic DNA from citrated whole blood. Biochem J (1991) 0.91
Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost (2000) 0.91
Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women. Haemophilia (2009) 0.90
Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost (2005) 0.90
Hypofibrinogenemia in non-M3 acute myeloid leukemia. Incidence, clinical and laboratory characteristics and prognosis. Leukemia (1998) 0.90
Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke. Thromb Haemost (1998) 0.90
Low-density lipoprotein receptor-related protein 1 polymorphism 663 C > T affects clotting factor VIII activity and increases the risk of venous thromboembolism. J Thromb Haemost (2006) 0.89
Lepirudin blunts endotoxin-induced coagulation activation. Blood (2000) 0.89
Role of von Willebrand factor in vascular disease. Hamostaseologie (2009) 0.89
A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood (1998) 0.89
Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma. J Thromb Haemost (2012) 0.89
Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J (2000) 0.89
Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. Circulation (1997) 0.88
Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism. Thromb Haemost (2001) 0.88